# US 2006/0051379 A1 · Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051379 A1
- Document ID: US20060051379A1
- Status: Published application
- Kind: A1
- Application number: 10/523,044
- Filed: 2003-07-31
- Published: 2006-03-09
- Earliest claimed: 2002-08-02
- Assignees: Glaxosmithkline Biologicals SA
- Inventors: Ralph Biemans; Philippe Denoel; Christiane Feron; Carine Goraj; Jan Poolman; Vincent Weynants
- Web page: https://patentgrep.com/patent/US20060051379A1

## CPC

- A61K 39/095: Neisseria
- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- A61K 39/1045: {Moraxella}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/22: from Neisseriaceae (F)
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/70: {Multivalent vaccine}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and Opc, and PorA and OpA and OpC. Alternatively, or in addition, lgtB− is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions. Bleb vaccines derived from lgtB− and capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.

## Claims

### Claim 1

A Neisserial bleb preparation derived from a neisserial strain with an L2 LOS immunotype or a neisserial strain with an L3 LOS immunotype and wherein the strain is lgtB−; or a Neisserial bleb preparation comprising a combination of blebs derived from a neisserial strain with an L2 LOS immunotype and a neisserial strain with an L3 LOS immunotype, optionally wherein each strain is lgtB−.

### Claim 2 (depends on 1)

The Neisserial bleb preparation of claim 1, comprising a neisserial strain selected from the group of a meningococcal strain and a strain of serogroup B.

### Claim 3 (depends on 1)

The Neisserial bleb preparation of claim 1, wherein the neisserial strain(s) cannot synthesize capsular polysaccharide.

### Claim 4 (depends on 3)

The Neisserial bleb preparation of claim 3, wherein the neisserial strain(s) have at least one of the following capsular polysaccharide genes downregulated in expression, or deleted compared to the native strain(s) from which they are derived selected from the group of: ctrA, ctrB, ctrC, ctrD, synA, synB, synC, and saiD; and wherein L2 and L3 blebs are both present, and optionally the strains from which they are derived have the same capsular polysaccharide gene downregulated in expression in each-strain.

### Claim 5 (depends on 1)

The Neisserial bleb preparation of claim 1, wherein the neisserial strain(s) have either or both of the following lipid A genes downregulated in expression, or deleted, compared to the native strain(s) from which they are derived: msbB or htrB and wherein L2 and L3 blebs are both present; and optionally the strains from which they are derived have the same lipid A gene(s) downregulated in expression in each strain.

### Claim 6 (depends on 1)

The Neisserial bleb preparation of claim 1, wherein the neisserial strain(s) have 1 or more of the following outer membrane protein genes downregulated in expression or deleted, compared to the native strain(s) from which they are derived: porA, porB, opA, opC, pilC or frpB; and wherein where L2 and L3 blebs are both present, and optionally the strains from which they are derived preferably have the same outer membrane protein gene(s) downregulated in expression in each strain.

### Claim 7 (depends on 6)

The Neisserial bleb preparation of claim 6, wherein the neisserial strain(s) have any of the following combinations of outer membrane protein genes downregulated in expression, or deleted, compared to the native strain(s) from which they are derived: PorA and OpA, PorA and OpC, OpA and OpC, PorA and OpA and OpC, PorA and FrpB, OpC and FrpB, OpA and FrpB, PorA and OpA and OpC and FrpB.

### Claim 8 (depends on 1)

The Neisserial bleb preparation of claim 1, wherein the neisserial strain(s) have 1 or more of the following outer membrane protein antigens upregulated in expression: NspA, TbpA low, TbpA high, Hsf, Hap, OMP85, PilQ, NadA, LbpA, MltA; and wherein where L2 and L3 blebs are both present, and optionally the strains from which they are derived have one or more different outer membrane protein antigens upregulated in expression in each strain.

### Claim 9

A Neisserial bleb preparation derived from a neisserial strain which has had 2 or more of the following outer membrane proteins downregulated in expression, or deleted, compared to the native strain from which it is derived: PorA, PorB, OpA, OpC, PilC, or FrpB.

### Claim 10 (depends on 9)

The Neisserial bleb preparation of claim 9, wherein the neisserial strain has had any of the following combinations of outer membrane proteins downregulated in expression, or deleted, compared to the native strain from which it is derived: PorA and OpA, PorA and OpC, OpA and OpC, PorA and OpA and OpC, PorA, and FrpB, OpC and FrpB, OpA and FrpB, PorA and OpA and OpC and FrpB.

### Claim 11 (depends on 1)

The Neisserial strain(s) from which the Neisserial bleb preparations of are claim 1 is derived.

### Claim 12 (depends on 11)

A LOS preparation isolated from the Neisserial strain(s) of claim 11 comprising immunotype L2 or L3 LOS.

### Claim 13 (depends on 12)

The LOS preparation of claim 12 in a liposome formulation.

### Claim 14 (depends on 1, 12)

The Neisserial bleb preparation of claim 1 or the LOS preparation of claim 12, wherein the LOS contained therein is conjugated to a source of T-helper epitopes.

### Claim 15 (depends on 14)

The Neisserial bleb preparation of claim 14 obtained through a process of intra-bleb cross-linking.

### Claim 16 (depends on 1)

An immunogenic composition or vaccine comprising the Neisserial bleb preparation or the LOS preparation of claim 1, and a pharmaceutically acceptable excipient.

### Claim 17 (depends on 16)

The vaccine of claim 16, comprising an adjuvant, preferably aluminium hydroxide, or 3D-MPL and aluminium phosphate.

### Claim 18 (depends on 16)

The vaccine of claim 16 comprising one or more conjugated capsular polysaccharides or oligosaccharides derived from the strains selected from the group of: meningococcus serogroup A, meningococcus serogroup C, meningococcus serogroup W-135, meningococcus serogroup Y, and H. influenzae type b.

### Claim 19 (depends on 11, 16)

A process of manufacturing the Neisserial bleb preparation vaccine of claim 16 comprising the steps of culturing the Neisserial strain(s) of claim 11, isolating blebs therefrom, optionally combining L2 and L3 blebs, and formulating the blebs with a pharmaceutically acceptable excipient.

### Claim 20 (depends on 19)

The process of claim 19, wherein the isolation step is carried out by extracting with 0.1%, about 0-0.5, about 0.02-0.4, about 0.04-0.3, about 0.06-0.2, or about 0.08-0.15% deoxycholate.

### Claim 21

A bleb preparation from a Gram-negative bacterial strain comprising an outer-membrane protein conjugated to LOS integrated in the outer-membrane.

### Claim 22 (depends on 21)

The bleb preparation of claim 21, wherein more than 10, 20, 30, 40, 50, 60, 70, 80, 90, 95 or 99% of the conjugated LOS has a lipid A moiety integrated in the outer-membrane of the bleb or in an environment whereby its toxicity is reduced or shielded from a host to which it has been administered.

### Claim 23 (depends on 21)

The bleb preparation of claim 21, wherein the toxicity of the LOS in the bleb is reduced compared to the blebs with the same amount of unconjugated LOS.

### Claim 24 (depends on 21)

The bleb preparation of claim 21, wherein more than 10, 20, 30, 40, 50, 60, 70, 80, 90, 95 or 99% of the conjugated LOS is in a native conformation that induces a bactericidal antibody response against it when administered to a host's immune system.

### Claim 25 (depends on 21)

The bleb preparation of claim 21, wherein the conjugated LOS has a conformation that elicits an immune response in a host reactive against unconjugated LOS.

### Claim 26 (depends on 21)

The bleb preparation of claim 21, wherein the outer-membrane protein is conjugated to the oligosaccharide or polysaccharide moiety of the LOS molecule.

### Claim 27 (depends on 21)

The bleb preparation of claim 21, wherein the outer-membrane protein and LOS molecule are native to the Gram-negative bacterial strain from which the blebs are derived.

### Claim 28 (depends on 21)

The bleb preparation of claim 21 obtained by a process of intra-bleb cross-linking.

### Claim 29 (depends on 21)

The bleb preparation of claim 21 wherein more than 10, 20, 30, 40, 50, 60, 70, 80, 90, or 95% of the LOS present in the blebs is cross-linked or conjugated to outer membrane protein.

### Claim 30 (depends on 21)

The bleb preparation of claim 21 derived from a Gram-negative strain that does not produce capsular polysaccharide, or from a bleb preparation that does not comprise capsular polysaccharide.

### Claim 31 (depends on 21)

The bleb preparation of claim 21, wherein capsular polysaccharide is not conjugated to an outer-membrane protein integrated in the bleb preparation.

### Claim 32 (depends on 21)

The bleb preparation of claim 21 derived from a Moraxella catarrhalis or a non-typeable Haemophilus influenzae strain.

### Claim 33 (depends on 21)

The bleb preparation of claim 21 derived from a strain selected from the group of a Neisserial strain and Neisseria meningitis.

### Claim 34 (depends on 33)

The bleb preparation of claim 33, wherein the bleb preparation comprises conjugated L2 LOS, conjugated L3 LOS, or a mixture of conjugated L2 and L3 LOS optionally separately conjugated to at least 2 different blebs.

### Claim 35 (depends on 33)

The bleb preparation of claim 33 derived from lgtB− strains, or wherein the LOS has a truncated structure consistent with it having been derived from a strain which is lgtB−.

### Claim 36 (depends on 32)

The bleb preparation of claim 32, derived from htrB− or msbB− strains, or wherein the LOS Lipid A moiety lacks secondary acyl chains consistent with it having been isolated from a htrB−or msbB− meningococcal strain.

### Claim 37 (depends on 21)

An immunogenic composition or vaccine comprising the bleb preparation of claim 21, and a pharmaceutically acceptable excipient.

### Claim 38 (depends on 37)

The immunogenic composition or vaccine of claim 37 additionally comprising an adjuvant.

### Claim 39 (depends on 37)

The immunogenic composition or vaccine of claim 37 comprising one or more conjugated capsular polysaccharides or oligosaccharides derived from the following strains: meningococcus serogroup A, meningococcus serogroup C, meningococcus serogroup W-135, meningococcus serogroup Y, and H. influenzae type b.

### Claim 40

A process of producing an intra-bleb conjugated bleb preparation from a Gram-negative bacterial strain comprising an outer-membrane protein conjugated to LOS integrated in the outer-membrane, comprising the steps of:
a) isolating blebs from the Gram-negative strain,
b) carrying out a method for conjugating the oligosaccharide moiety of the LOS present in the blebs to an outer membrane protein present on the same bleb,
c) isolating the intra-bleb conjugated bleb preparation, and
d) optionally formulating the intra-bleb conjugated bleb preparation with a further intra-bleb conjugated bleb preparation made by the same process but having a different LOS immunotype and optionally formulating the bleb preparation with a pharmaceutically acceptable excipient to make a vaccine composition.

### Claim 41 (depends on 40)

The process of claim 40 wherein step a) the blebs are extracted using a of deoxycholate of about 0-0.3%, or about or exactly 0.1%.

### Claim 42 (depends on 40)

The process of claim 40, wherein in step b) the pH is kept between 7 and 9, or at around pH 7.5.

### Claim 43 (depends on 40)

The process of claim 40, wherein step b) is carried out in about 1-5% sucrose.

### Claim 44 (depends on 40)

The process of claim 40, wherein step b) is carried out in low NaCl concentration conditions.

### Claim 45 (depends on 40)

The process of claim 40, wherein step b) is carried out with a method comprising EDAC/NHS chemistry.

### Claim 46 (depends on 40)

The process of claim 40, wherein in step a) the blebs are isolated from a strain selected from the group of a neisserial strain, a meningococcal strain, and a meningococcus B strain.

### Claim 47 (depends on 46)

The process of claim 46 wherein the strain is selected from the group of one that cannot make capsular polysaccharide, and a mutant strain.

### Claim 48 (depends on 46)

The process of claim 46 wherein the strain is an lgtB− mutant.

### Claim 49 (depends on 46)

The process of claim 46 wherein the strain is msbB− or htrB−.

### Claim 50 (depends on 46)

The process of claim 46 wherein the strain has an L2 LOS immunotype.

### Claim 51 (depends on 46)

The process of claim 46 wherein the strain has an L3 LOS immunotype.

### Claim 52 (depends on 46, 50)

The process of claim 46 wherein in step d) a meningococcal intra-bleb conjugated bleb preparation with an L2 immunotype made by the process of claim 50 is combined with a further meningococcal intra-bleb conjugated bleb preparation with an L3 immunotype.

### Claim 53 (depends on 14)

The Neisserial bleb preparation of claim 14 wherein the source of T-helper epitopes comprises a protein or outer membrane protein.

### Claim 54 (depends on 46, 51)

The process of claim 46 wherein in step d) a meningococcal intra-bleb conjugated bleb preparation with an L2 immunotype is combined with a further meningococcal intra-bleb conjugated bleb preparation with an L3 immunotype made by the process of claim 51.

### Claim 55 (depends on 38)

The immunogenic composition or vaccine of claim 38 wherein the adjuvant is aluminum hydroxide or 3D-MPL and aluminum phosphate.
